Articles tagged "HLA antibodies"

2019 American Transplant Congress
“Desens Light”: Single Center Experience Using Rituximab for High Immunologic Risk Kidney Transplant Recipients with Historic DSA
A. Casillas-Abundis, A. Tambur, A. Shetty, C. D'Agostino, J. R. Leventhal
Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, IL
*Purpose: To evaluate the effectiveness of rituximab as induction therapy for pts undergoing kidney transplant (Tx) with historic DSA (hDSA) [Desens. Light].*Methods: 104 consecutive pts…
2019 American Transplant Congress
Immunologic Impact Of Native Kidney Function On Liver Transplant Patients
M. Mujtaba, S. Merwat, J. Fair, M. Bilal, A. Chatila, R. Kulkarni, J. Zou, S. Hussain, A. Gamilla-Crudo
Univ. of Texas Medical Branch, Galveston, TX
*Purpose: Renal failure in the setting of liver transplantation (LTx) is common and has an adverse impact on short and long-term graft and patient survival.…
2019 American Transplant Congress
Mismatched Epitope and De Novo DSA Development: An Analysis of the Benefit and Benefit-EXT Renal Transplant Cohorts
V. Jucaud¹, V. Burnett¹, H. Gebel², R. Bray², M. Polinsky³, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Emory University, Atlanta, GA, ³Bristol-Myers Squibb, Princeton, NJ
*Purpose: De novo donor-specific HLA antibodies (dnDSA) target epitopes rather than whole antigens, and their development is associated with the mismatched HLA antibody epitope load…
2019 American Transplant Congress
Clazakizumab Acts on Endothelial Cells to Limit Antibody Mediated Damage
J. Lion¹, K. Poussin¹, E. Chong², D. Glotz³, N. A. Mooney¹
¹Alloimmunité-Autoimmunité-Transplantation, INSERM, Paris, France, ²Vitaeris, Vancouver, BC, Canada, ³Nephrology and Transplantation, Hôpital Saint Louis, Paris, France
*Purpose: Human microvascular endothelial cell expression of HLA class II antigens is strongly increased, both in vitro and in vivo, under inflammatory conditions. HLA class…
2019 American Transplant Congress
Efficacy Of Rituximab Monotherapy On Anti-human Leukocyte Antigen Antibodies In Highly Sensitized Living Donor Kidney Transplant Patients.
D. J. Sindi¹, A. Al Jedai², H. Aleid³, J. Brockmann⁴, M. Al-Awwami⁵, D. Alissa², E. De Vol⁶, H. Al Khabbaz⁷, L. Fajji⁸
¹Clinical Pharmacy, King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh, Saudi Arabia, ²Clinical Pharmacy, KFSH&RC, Riyadh, Saudi Arabia, ³Kidney and Pancreas transplantation, KFSH&RC, Riyadh, Saudi Arabia, ⁴kFSH&RC, Riyadh, Saudi Arabia, ⁵Clinical Director, Histocompatibility and Immunogenetics Laboratory, KFSH&RC, Riyadh, Saudi Arabia, ⁶KFSH&RC, Riyadh, Saudi Arabia, ⁷Riyadh Elm University, Riyadh, Saudi Arabia, ⁸Clinical Transplant Coordinator, KFSH&RC, Riyadh, Saudi Arabia
*Purpose: We aim to examine the efficacy of Rituximab (RTX) monotherapy in reducing DSA in Highly Sensitised Living Donor Kidney Transplant (HS-LDKT) candidates and potentially…
2019 American Transplant Congress
Mismatched Antibody Epitopes and the Development of HLA-DQ De Novo DSA during Immunosuppression Withdrawal in Liver Transplant Recipients
V. Jucaud¹, A. Shaked², M. DesMarais³, P. Sayre⁴, S. Feng⁴, J. Levitsky⁵, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²University of Pennsylvania, Philadelphia, PA, ³Immune Tolerance Network, San Francisco, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵Northern Western University, Chicago, IL
*Purpose: We recently described, in liver transplant (LT) recipients from the ITN030ST study, the development of de novo donor-specific HLA antibodies (dnDSA) and their impact…
2019 American Transplant Congress
Successful Kidney Transplantation of Highly Sensitized Candidates across Positive Cross Match and Strong Donor-Specific HLA-DP Antibodies without Desensitization
R. Rajalingam¹, D. D. Gae², Z. G. Laszik³, M. M. Tavakol⁴, A. B. Webber⁵, K. Cunniffe², G. da Gente², R. Hirose⁴, G. Roll⁴, C. E. Freise⁴, J. P. Roberts⁴
¹Immunogenetics and Transplantation Laboratory (ITL), San Francisco, CA, ²Department of Surgery, Immunogenetics and Transplantation Laboratory (ITL), San Francisco, CA, ³Department of Pathology, University of California San Francisco, San Francisco, CA, ⁴Department of Surgery, University of California San Francisco, San Francisco, CA, ⁵Department of Medicine, University of California San Francisco, San Francisco, CA
*Purpose: Over 50% of kidney transplant (Ktx) candidates with 100% CPRA display HLA-DP antibodies, which impair the chances of finding a compatible deceased donor (DD)…
2019 American Transplant Congress
Characterization of HLA Antibodies by C3d Assay and IgG Subclasses in Sensitized Kidney Transplant Patients
A. Casillas-Abundis, J. M. Arreola-Guerra, J. Alberu, M. I. Solis-G, L. Llorente, J. Granados, M. Vilatoba, R. Cruz-Martinez, L. Morales-Buenrostro, A. G. Contreras
Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico
*Purpose: To determine the detection rate of IgG subclasses (IgGsc) and C3d-binding HLA-antibodies (abs) in a cohort of highly sensitized kidney transplant patients.*Methods: We evaluated,…
2019 American Transplant Congress
Living Donor Renal Transplantation without Any Induction Immunosuppression in Spousal Donors – Single Center Experience
R. Bhat, F. Aziz, I. N. Abubecker, S. Narayanan, B. Hafeeque
Nephrology & Transplantation, Malabar Instiute of Medical Sciences, Calicut, India
*Purpose: Renal transplantation in India is primarily driven by living related donation; parents and spouse constitute 70% of donors in India. Some centres use induction…
2019 American Transplant Congress
Targeted Epitope Mutagenesis as a Strategy to Decrease Xenoantibody Binding
J. Ladowski, G. Martens, Z. Wang, L. Reyes, M. Tector, J. Tector
University of Alabama-Birmingham, Birmingham, AL
*Purpose: Xenotransplantation, the use of genetically-modified pig organs for transplantation, has been limited by antibody-mediated rejection. The generation of a three-antigen knockout pig provided a…